drugset / Trial / NCT00079872

Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer

NCT00079872 ↗

Phase 2 Completed 120 enrolled Eli Lilly and Company
RandomizedFactorialOpen-labelTreatment

Summary

In this study, patients will receive either pemetrexed plus irinotecan or 5-fluorouracil (5-FU), leucovorin, and irinotecan. The purposes of this study are to determine: * How pemetrexed plus irinotecan compares with 5-FU, leucovorin, and irinotecan in terms of efficacy. * The safety of pemetrexed plus irinotecan and any side effects that might be associated with it as compared with 5-FU, leucovorin, and irinotecan. * Whether pemetrexed can help patients with colorectal cancer.

Timeline

Start
2004-02
Primary completion
—
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule — —

Indications